|
|
적색스테인
|
|
 |
HOxbLZxjyeF |
 |
386 |
|
 |
| I'm retired http://cam4.in.net/ ca4 On Wednesday, Pfizer said tofacitinib met its primary effectiveness goal in a separate Phase III psoriasis study, called OPT Retreatment, which lasted 56 weeks and compared the 5 milligram and 10 milligram doses of tofacitinib to a placebo. |
|
 |
Bradford |
 |
2019-08-06 14:57:01 |
|
|
|
|
|
|
|
|
|
